Latest News & Features
Americas
The US Court of Appeals for the Federal Circuit has reversed a $482 million jury decision against Johnson & Johnson subsidiary Cordis, ruling that its Cypher stent did not infringe a patent held by radiologist Bruce Saffran. 8 April 2013
Asia
India’s Supreme Court has rejected pharmaceutical company Novartis’s application to patent an updated version of its leukaemia drug Glivec, agreeing with the Comptroller General that it lacked novelty. 3 April 2013
Asia
India’s patent office has published final guidelines for examining biotechnology patents, after accepting comments on a draft version published in December. 2 April 2013
Asia
There are important differences between the Russian and Eurasian procedures in obtaining a patent, especially for inventions in the field of life sciences, as Maria Nilova and Elena Tsvetkova explain. 1 April 2013
Americas
While no court has tested it, Brazilian legislation seems to prohibit pay-for-delay settlements in the pharmaceutical industry. Gabriel Di Blasi argues that it’s time for a test case. 1 April 2013
Americas
Biocomparable medicines are currently among the hottest topics in regard to life sciences legislation in Mexico. Daniel Sánchez and Victor Ramirez investigate. 1 April 2013
Americas
The sweeping reform brought about by the AIA includes the FITF patent system, which places a premium
on maintaining confidentiality, and speed and efficiency in filing patent applications while juggling the uncertainties and nuances of this new system. 1 April 2013
Americas
Challenging the validity of a patent through the court systems of Europe and the US can be a time-consuming and expensive process. Jane Wainwright and Daniel Young look at the alternatives. 1 April 2013
Asia
Therapeutic substances used under the folk medicine practices of what is known as ‘traditional knowledge’ are protected by special provisions under Indian patent law. Archana Shanker and Vidisha Garg explore the pros and cons. 1 April 2013
Biotechnology
In its effort to tackle the threat of ‘evergreening’, the CJEU has caused some uncertainty about supplementary protection certificates, as Jaap Mannaerts explains. 1 April 2013